Zentails announced the first dosage of Azenosertib administered in its phase III Aspenova trial to test azenosertib vs chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer.
Zentalis Pharmaceuticals has dosed the first patient in Aspenova, a global phase III trial evaluating the oral WEE1 inhibitor azenosertib against investigator’s choice chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
Platinum-resistant ovarian cancer remains a difficult treatment setting. Standard nonplatinum options enerally offer modest response rates and limited progression-free survival, while cumulative toxic effects and prior bevacizumab or PARP inhibitor exposure can further narrow choices.2,3
Current NCCN guidance lists sequential single-agent therapy as a common approach in platinum-resistant disease, underscoring the need for better-tolerated and more active therapies for molecularly defined subsets.3
The study is intended as a confirmatory trial as part of a development program including the registration-intended phase II Denali study and could help define whether biomarker selection for WEE1 inhibition improves outcomes in a setting where treatment options remain limited.1,4
“Dosing the first patient in the Aspenova Phase III clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, MD, chief medical officer of Zentalis, in the company’s release.1
Aspenova enrolled approximately 420 patients with Cyclin E1-positive PROC and randomized them to azenosertib 400 mg once daily on a 5-days-on, 2-days-off schedule or to single-agent chemotherapy selected by the investigator: paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan.1
The primary end point of the trial was progression-free survival, with overall survival and overall response rate listed as key secondary end points. According to the company, the design was aligned with FDA as part of a potential accelerated approval pathway in which Denali could support an initial filing and Aspenova could serve as the confirmatory study.1
The strategy reflects a familiar regulatory model in oncology, but it also raises operational and evidentiary requirements, as confirmation of benefit in a biomarker-defined subgroup will depend not only on efficacy, but also on reproducible assay performance across regions and sites. Zentalis says validation of its Cyclin E1 companion diagnostic assay is ongoing in both Denali and Aspenova.1
Key limitations during this stage of testing includes, the absence of peer-reviewed data from Denali Part II, lack of disclosed safety tables for the selected dose, and uncertainty about how broadly the assay will perform in routine practice.
Azenosertib is an investigational oral inhibitor of WEE1, a kinase involved in cell-cycle checkpoint control through regulation of CDK1 and CDK2.1 The biologic rationale for WEE1 inhibition in Cyclin E1-driven tumors is based on replication stress and checkpoint dependence, a concept that has supported broader development of WEE1-targeted therapies in ovarian and other solid tumors.4 However, clinical proof in this specific biomarker-selected population remains pending.
Zentalis says an interim dose-confirmation analysis in Denali Part IIa favored the 400-mg 5:2 schedule over 300 mg 5:2 for response rate, with “comparable safety profiles,” but it did not disclose numerical efficacy or adverse event data.1 Without those details, the magnitude of potential benefit and tolerability relative to standard chemotherapy cannot yet be independently assessed.
Fiona Simpkins, MD, professor at the University of Pennsylvania Perelman School of Medicine and lead investigator for Aspenova, said: “Cyclin E1-overexpressing ovarian cancers are associated with platinum-resistance and poor outcomes, representing a clinical unmet need.”
Next steps include continued enrollment in Aspenova and completion of Denali Part II, which Zentalis expects a topline readout by the end of 2026.1
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
